Free Trial

Vaccine Headline Sensitivity

US TSY FUTURES

Bit of a knee-jerk reaction to latest vaccine related headlines from Pfizer last few minutes, announcing 95% effectiveness vs. 90% that sent markets on a risk-asset buy spree last week Monday. Tsys pared gains, extending overnight lows. Futures rebound back to prior lvls, perhaps as storage and distribution issues remain.

  • 3M10Y +0.237, 77.318 (L: 74.542 / H: 78.135)
  • 2Y10Y +0.081, 68.666 (L: 66.293 / H: 69.283)
  • 2Y30Y -0.344, 143.196 (L: 140.068 / H: 143.667)
  • 5Y30Y -0.582, 121.998 (L: 119.813 / H: 122.777)
  • Current futures levels:
  • Dec 2Y down 0.12/32 at 110-11.625 (L: 110-11.5 / H: 110-12)
  • Dec 5Y down 0.5/32 at 125-17 (L: 125-16.5 / H: 125-19.25)
  • Dec 10Y steady at 138-9.5 (L: 138-08 / H: 138-16.5)
  • Dec 30Y up 7/32 at 172-25 (L: 172-20 / H: 173-15)
  • Dec Ultra 30Y up 19/32 at 216-18 (L: 216-09 / H: 218-03)

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.